Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003269 · ClinicalTrials.gov registry record · Phase 2
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
A Phase 2 study, sponsored by Scripps Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00003269 is a Phase 2 study that has completed, run by Scripps Health. The registered enrollment target is 20 participants.
The verdict
NCT00003269, a Phase 2 study, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of amifostine followed by high-dose chemotherapy in treating patients with hematologic cancer or solid tumors.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL sargramostim
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1998-02 |
| Est. Completion | 2001-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003269
The ClinicalTrials.gov registry entry for NCT00003269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Health, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003269 about?
NCT00003269 is a clinical study titled "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of amifostin...
What is the current status of trial NCT00003269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1998-02. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00003269?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), sargramostim (BIOLOGICAL), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003269?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.